Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Current Issues in Pharmacy and Medical Sciences

Formerly Annales UMCS Sectio DDD Pharmacia

4 Issues per year


CiteScore 2016: 0.19

SCImago Journal Rank (SJR) 2016: 0.132
Source Normalized Impact per Paper (SNIP) 2016: 0.119

Open Access
Online
ISSN
2300-6676
See all formats and pricing
More options …

Overview on fosfomycin and its current and future clinical significance

Beata Chudzik-Rzad
  • Corresponding author
  • Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sylwia Andrzejczuk
  • Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mariusz Rzad / Krzysztof Tomasiewicz
  • Chair and Clinic Infection Diseases, Independent Public Teaching Hospital No 1 in Lublin, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anna Malm
  • Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2015-05-09 | DOI: https://doi.org/10.1515/cipms-2015-0039

Abstract

Fosfomycin is an old antibiotic with a unique chemical structure and with broadspectrum activity against numerous bacterial pathogens, both Gram-positive and Gramnegative, including resistant and multi-resistant strains. This antibiotic was accepted into clinical practice in the early 1970s. Its use, however, has been limited for several years for treating mainly lower uncomplicated urinary tract infections (in the form of fosfomycin trometamol taken orally). Nowadays, many clinicians and scientists are looking at this antibacterial drug for its employment in the treatment of severe infections caused by multi-resistant bacteria. Fosfomycin as an intravenous formulation (fosfomycin disodium) achieves clinically relevant concentrations in the serum and the cerebrospinal fluid, in kidney, bladder wall, prostate, lungs, bone and heart valves tissues, as well as in inflamed tissues and abscess fluid. The available clinical studies confirmed the efficacy of intravenous fosfomycin for the management of severe infections caused by multiresistant pathogens.

Keywords: fosfomycin; urinary tract infections; multi-resistant bacterial infections

References

  • 1. Allerberger F., Klare I.: In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J. Antimicrob. Chemother., 43, 211, 1999.CrossrefGoogle Scholar

  • 2. Bader M.S., Hawboldt J., Brooks A.: Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad. Med., 122, 7, 2010.CrossrefWeb of ScienceGoogle Scholar

  • 3. Baltz R.H., Daptomycin: mechanisms of action and resistance and biosynthetic engineering. Curr. Opin. Chem. Biol., 13, 144, 2009.CrossrefWeb of ScienceGoogle Scholar

  • 4. Baylan O.: Fosfomycin: past, present and future. Mikrobiyol. Bul., 44, 311, 2010.Google Scholar

  • 5. Bayrak O. et al.: Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int. Urogynecol. J., 18, 525, 2007.Web of ScienceCrossrefGoogle Scholar

  • 6. Bocher H.W. et. al.: Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 48, 1, 2009.CrossrefGoogle Scholar

  • 7. Cassir N., Rolain J.M., Brouqui P.: A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front. Microbiol., 5, 1, 2014.CrossrefWeb of ScienceGoogle Scholar

  • 8. Chareancholvanich K., Udomkiat P., Waikakul S.: A randomized control trial between fosfomycin and cefuroxime as the antibiotic prophylaxix in knee arthroplasty. J. Med. Assoc. Thai., 9, 6, 2012.Google Scholar

  • 9. Chen L.Y. et al.: High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report. BMC. Infect. Dis., 11, 1, 2011.Web of ScienceCrossrefGoogle Scholar

  • 10. Eschenburg S., Priestman M., Schonbrunn E.: Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J. Biol. Chem., 280, 3757, 2005.Google Scholar

  • 11. Falagas M.E. et al.: Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimentaland clinical evidence. J. Antimicrob. Chemother., 60, 7, 2007.CrossrefGoogle Scholar

  • 12. Falagas M.E. et al.: Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis., 46, 1069, 2008.Web of ScienceCrossrefGoogle Scholar

  • 13. Falagas M.E. et al.: Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents., 34, 111, 2009.Web of ScienceCrossrefGoogle Scholar

  • 14. Falagas M.E.et al.: Fosfomycin for the treatment of multidrugresistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet. Infect. Dis., 10, 43, 2010.CrossrefGoogle Scholar

  • 15. Falagas M.E. et al.: Antimicrobial susceptibility of multidrugresistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents., 35, 240, 2010.CrossrefGoogle Scholar

  • 16. Gardiner B.J., et al.: Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin. Infect. Dis., 58, 101, 2014.Web of ScienceCrossrefGoogle Scholar

  • 17. Giamarellou H.: Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents., 36, 50, 2010.Web of ScienceCrossrefGoogle Scholar

  • 18. Hamilton-Miller J.M.: In vitro activity of fosfomycin against “problem” Gram-positive cocci. Microbios., 1992, 71: 95-103.Google Scholar

  • 19. Hauser C. et al.: In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob. Agents. Chemother., 59, 1605, 2015.Web of ScienceCrossrefGoogle Scholar

  • 20. Kaase M. et al.: Fosfomycin in susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J. Clin. Microbiol. 52, 1893, 2014.CrossrefWeb of ScienceGoogle Scholar

  • 21. Kahan FM. et al.: The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci., 235, 364, 1974.Google Scholar

  • 22. Karageorgopoulos D.E. et al.: Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J. Antimicrob. Chemother., 67, 255, 2012.CrossrefWeb of ScienceGoogle Scholar

  • 23. Keating G.M.: Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs., 73, 1951, 2013.CrossrefWeb of ScienceGoogle Scholar

  • 24. Ko K.S. et al.: In vitro activity of fosfomycin against ciprofloxacinresistant or extended-spectrum β-lactamase-producing Escherichia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis., 58, 111, 2007.CrossrefGoogle Scholar

  • 25. Lepe J.A. et al.: In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes. Int. J. Antimicrob. Agents., 43, 135, 2014.CrossrefWeb of ScienceGoogle Scholar

  • 26. Livermore D.M. et al.: What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocyllin and tigecycline. Int. J. Antimicrob. Agents., 37, 415, 2011.CrossrefGoogle Scholar

  • 27. Lu C.L. et al.: Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother., 55, 4295, 2011.Google Scholar

  • 28. Mazzei T. et al.: Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. J. Antimicrob. Agents., 28, 35, 2006.CrossrefGoogle Scholar

  • 29. Michalopoulos A.S., Livaditis I.G., Gougoutas V.: The revival of fosfomycin. Int. J. Infect. Dis., 15, 732, 2011.Web of ScienceCrossrefGoogle Scholar

  • 30. Michalopoulos A. et al.: Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect., 16, 184, 2010.Web of ScienceCrossrefGoogle Scholar

  • 31. Pontikis K. et al.: Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrugresistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int. J. Antimicrob. Agents., 43, 52, 2014. CrossrefGoogle Scholar

  • 32. Poulakou G. et al.: Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future. Microbiol., 9, 1053, 2014.CrossrefWeb of ScienceGoogle Scholar

  • 33. Raz R.: Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect., 18, 4, 2012.CrossrefGoogle Scholar

  • 34. Reffert J.L., Smith W.J.: Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the society of infectious diseases pharmacists. Pharmacotherapy., 34, 845, 2014.Web of ScienceCrossrefGoogle Scholar

  • 35. Ruxer J. et al.: Fosfomycin, co-trimoxazole and nitrofurantoin in the treatment of recurrent uncomplicated urinary tract infections in type 2 diabetes mellitus. Wiad. Lek., 60, 235, 2007.Google Scholar

  • 36. Sultan A. et al.: Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol. Ann., 7, 26, 2015.CrossrefGoogle Scholar

  • 37. Trubiano J.A. et al.: The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br. J. Clin. Pharmacol., 79, 195, 2015.Web of ScienceCrossrefGoogle Scholar

  • 38. Wang A. et al.: Urinary tract infections. Prim. Care., 40, 687, 2013. CrossrefGoogle Scholar

About the article

Received: 2015-03-02

Accepted: 2015-03-18

Published Online: 2015-05-09

Published in Print: 2015-03-01


Citation Information: Current Issues in Pharmacy and Medical Sciences, Volume 28, Issue 1, Pages 33–36, ISSN (Online) 2300-6676, ISSN (Print) 2084-980X, DOI: https://doi.org/10.1515/cipms-2015-0039.

Export Citation

© 2015. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in